<SEC-DOCUMENT>0001193125-22-230060.txt : 20220825
<SEC-HEADER>0001193125-22-230060.hdr.sgml : 20220825
<ACCEPTANCE-DATETIME>20220825162418
ACCESSION NUMBER:		0001193125-22-230060
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220825
DATE AS OF CHANGE:		20220825

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			biote Corp.
		CENTRAL INDEX KEY:			0001819253
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				851791125
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-265714
		FILM NUMBER:		221197700

	BUSINESS ADDRESS:	
		STREET 1:		1875 W. WALNUT HILL LN #100
		CITY:			IRVING
		STATE:			TX
		ZIP:			75038
		BUSINESS PHONE:		972-486-9346

	MAIL ADDRESS:	
		STREET 1:		1875 W. WALNUT HILL LN #100
		CITY:			IRVING
		STATE:			TX
		ZIP:			75038

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Haymaker Acquisition Corp. III
		DATE OF NAME CHANGE:	20200727
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d399424d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(3) <BR> Registration No. 333-265714 <BR> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT NO. 6 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To the Prospectus Dated
July&nbsp;19, 2022) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>biote Corp. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Up to 72,069,990 Shares of Class&nbsp;A Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Up to 67,856,462 Shares of Class&nbsp;A Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Up to 5,566,666 Warrants </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement supplements the prospectus dated July&nbsp;19, 2022 (the &#147;<B>Prospectus</B>&#148;), which forms a part of our
registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (No. <FONT STYLE="white-space:nowrap">333-265714),</FONT> as amended. This prospectus supplement is being filed to update and supplement the information in the Prospectus
with the information contained in our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed with the Securities and Exchange Commission on August&nbsp;25, 2022 (the &#147;<B>Current Report</B>&#148;). Accordingly, we have
attached the Current Report to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus and this prospectus supplement relate to the issuance by us of
an aggregate of up to up to 72,069,990 shares of our Class&nbsp;A Common Stock consisting of (i) 7,937,500 shares of Class&nbsp;A Common Stock issuable upon the exercise of 7,937,500 warrants (the &#147;<B>Public Warrants</B>&#148;) originally
issued in the initial public offering of Haymaker Acquisition Corp. III (the &#147;<B>IPO</B>&#148;) at a price of $10.00 per unit with each unit consisting of one share of HYAC Class&nbsp;A Common Stock (as defined in the Prospectus) and <FONT
STYLE="white-space:nowrap">one-fourth</FONT> of a Public Warrant, (ii) 5,566,666 shares of Class&nbsp;A Common Stock issuable upon the exercise of warrants (the &#147;<B>Private Placement Warrants</B>&#148; and together with the Public Warrants, the
&#147;<B>Warrants</B>&#148;), which were originally the Sponsor in connection with the IPO at a price of $1.50 per Private Placement Unit and (iii) 58,565,824 shares of Class&nbsp;A Common Stock issuable to the Members (as defined in the Prospectus)
upon exercise of the Retained Biote Units (as defined in the Prospectus) pursuant to the Exchange Rights (as defined in the Prospectus), which were originally issued at an assumed price per Retained Biote Unit of approximately $10.00. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Prospectus and this prospectus supplement relate to the offer and sale from time to time by the selling securityholders named
in the Prospectus or their permitted transferees (the &#147;<B>selling securityholders</B>&#148;) of (A) 67,856,462 shares of our Class&nbsp;A Common Stock, consisting of (i) 7,937,500 shares of Class&nbsp;A Common Stock originally issued in a
private placement to the Sponsor in connection with the IPO at a price of approximately $0.003 per share, (ii) 5,566,666 shares of Class&nbsp;A Common Stock issuable upon the exercise of the Private Placement Warrants and (iii) 54,352,296 shares of
Class&nbsp;A Common Stock issuable to the Members (as defined in the Prospectus) upon exercise of the Retained Biote Units (as defined in the Prospectus) pursuant to the Exchange Rights (as defined in the Prospectus) and (B) 5,566,666 Private
Placement Warrants, which Private Placement Warrants were originally issued at a purchase price of $1.50 per Private Placement Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Class&nbsp;A Common Stock and Public Warrants are quoted on the Pink Sheet Tier of the OTC Markets under the symbols &#147;BTMD&#148; and
&#147;BTMDW,&#148; respectively. For more details, please see our risk factor relating to a Nasdaq delisting beginning on page 43 of the Prospectus. On August&nbsp;24, 2022, the closing bid quotation of our Class&nbsp;A Common Stock and Public
Warrants were $4.15 and $0.26, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; and &#147;smaller reporting company&#148;
under applicable federal securities laws and will be subject to reduced public company reporting requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement
updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement
should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the
section titled &#147;Risk Factors&#148; beginning on page 8 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or
passed upon the accuracy or adequacy of this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date
of this prospectus supplement is August&nbsp;25, 2022 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 13 OR 15(D) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): August&nbsp;25, 2022 </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>biote Corp. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name
of registrant as specified in its charter) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-40128</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">85-1791125</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1875 W. Walnut Hill Ln #100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Irving, Texas 75038 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(844) <FONT STYLE="white-space:nowrap">604-1246</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbols</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Class&nbsp;A common stock, par value $0.0001 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>BTMD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>OTC Pink Open Market</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Warrants, each whole warrant exercisable for one share of Class&nbsp;A common stock, each at an exercise price of $11.50 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>BTMDW</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>OTC Pink Open Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencements</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT
STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;25, 2022, biote Corp. (the &#147;Company&#148;) issued a press release announcing the approval of its application to&nbsp;relist&nbsp;its
Class&nbsp;A common stock and warrants on The&nbsp;Nasdaq Stock Market LLC. The Company&#146;s Class&nbsp;A common stock and warrants will start trading under their existing symbols &#147;BTMD&#148; and &#147;BTMDW&#148;, respectively, at the open
of trading on August&nbsp;29, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exhibit attached hereto shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated August&nbsp;25, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOTE CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Teresa S. Weber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Teresa S. Weber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: August&nbsp;25, 2022 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g399424img001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Biote Announces Approval to Relist on The Nasdaq Stock Market </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company will resume trading under its existing symbols &#147;BTMD&#148; and &#147;BTMDW&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IRVING, TX, August</B><B></B><B>&nbsp;25, 2022 &#151;</B> <U>biote Corp. (&#147;Biote&#148; or the &#147;Company&#148;),</U> a high growth, differentiated
medical practice-building business within the hormone optimization space, today announced that The Nasdaq Stock Market LLC (&#147;Nasdaq&#148;) has approved its application for the relisting of the Company&#146;s common stock and warrants on The
Nasdaq Global Market. The Company&#146;s Class&nbsp;A common stock and warrants will resume trading effective with the open of the market on Monday, August&nbsp;29, 2022 under the Nasdaq ticker symbols &#147;BTMD&#148; and &#147;BTMDW,&#148;
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased to be back trading on Nasdaq,&#148; said Terry Weber, Chief Executive Officer of Biote. &#147;We appreciate the team
at Nasdaq for its prompt review of our application and for confirming that we meet all applicable initial listing criteria.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Biote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biote is a <FONT STYLE="white-space:nowrap">woman-led</FONT> company operating a high growth, differentiated medical practice-building business within the
hormone optimization space. Similar to a franchise model, Biote provides the necessary components to enable practitioners to establish, build, and successfully operate a hormone optimization center to treat patients appropriate for therapy. Biote
trains practitioners how to identify and treat early indicators of hormone-related aging conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains certain forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and
Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words &#147;may,&#148;
&#147;can,&#148; &#147;should,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;plan,&#148; &#147;project,&#148; &#147;forecast,&#148; &#147;intend,&#148; &#147;expect,&#148; &#147;hope,&#148; &#147;anticipate,&#148; &#147;believe,&#148;
&#147;seek,&#148; &#147;target,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;might,&#148; &#147;ongoing,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;would&#148; and other similar expressions, are intended to identify
forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many
factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the success of our dietary supplements to attain significant market acceptance
among clinics, practitioners and their patients; our customers&#146; reliance on certain third parties to support the manufacturing of <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormones for prescribers; our and our customers&#146;
sensitive to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow
our business; the significant competition we face in our industry; our limited operating history; our ability to protect our intellectual property; the unpredictability of the effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic;
the heavy regulatory oversight in our industry; changes in applicable laws or regulations; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business
and/or competitive factors and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g399424img001.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
uncertainties described in the &#147;Risk Factors&#148; section of Biote&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2022 and
other documents filed by Biote from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those
contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media&nbsp;Contact </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Press@biote.com</U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>IR@biote.com</U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g399424img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g399424img001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R
M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M            ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB2=-VTXP<<-GTKX'_P""MG[5?QB_95^'WPO\3^"_%-KX=N/&&J67A_5-(O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/[%?PI_VO"UB?RA05]QQ7E^&PV78>K1CRR:5_,]#'8>,*<;;O4]E0Y;\*=4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!LG0?6HVX%22=!]:C8\4#6Y^:O_  76.?B/
M\.U]+*\/_D2&O0O^"(OC+2[OX ^(-'CDC75[/6'GO(/XEBEC7RG/J#L;IG!&
M*X#_ (+I1;_B'\/VVDA;"\)./N@/$23^1_*OCKX#?';Q%^S?\0;'Q)X5O/LE
M\RF"6*9?,MKV$X)1L''4 ^M?DN-S2. S^5::NMC\FQ69+ Y_*K):'[QK)F(M
M@#;SSQCWK"^)7BJP\&^"-4U+6+B&STVTM9))YG(V!0IR.>I/0#N:^*?"7_!<
MWPZ-$_XGW@O7K/4@NT_8YH;BV<^Q9D(S]#]#7SI^VG_P4J\2?M602:!;V/\
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M%B.<9QG'O7Y5>"?^#@;XL>-/C_H-M;^"?#$WAW6+^"P30X#++>O&[A3+'/\
MQR '."@7K7Z^:8BD>8J[3)\S>V><?AG&?:OD>)JN;<U.GF36VB7_  #R\=+$
M:*L7****^6//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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,4E*5VR>BBBLR3__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
